Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Collegium Pharmaceutical (COLL) EBITDA Margin (2016 - 2026)

Collegium Pharmaceutical has reported EBITDA Margin over the past 10 years, most recently at 29.57% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 863.0% year-over-year to 29.57%; the TTM value through Dec 2025 reached 23.01%, down 1237.0%, while the annual FY2025 figure was 23.55%, 397.0% down from the prior year.
  • EBITDA Margin for Q4 2025 was 29.57% at Collegium Pharmaceutical, roughly flat from 29.66% in the prior quarter.
  • Over five years, EBITDA Margin peaked at 437.62% in Q3 2024 and troughed at 275.52% in Q1 2022.
  • A 5-year average of 23.22% and a median of 20.36% in 2021 define the central range for EBITDA Margin.
  • Biggest five-year swings in EBITDA Margin: soared 40469bps in 2024 and later plummeted -40797bps in 2025.
  • Year by year, EBITDA Margin stood at 89.02% in 2021, then soared by 110bps to 9.07% in 2022, then surged by 354bps to 41.2% in 2023, then tumbled by -49bps to 20.95% in 2024, then surged by 41bps to 29.57% in 2025.
  • Business Quant data shows EBITDA Margin for COLL at 29.57% in Q4 2025, 29.66% in Q3 2025, and 18.67% in Q2 2025.